top of page
gradientForSurfBreak.png

Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

Portfolio Company

Carlsmed.png

Top 20 UK and EU Artificial Intelligence Startups To Look Out For in 2024 ...

TechRound

Portfolio Company

Carlsmed.png

Skin Analytics looks to remap patient pathways for cancer diagnoses ...

Digital Health

General News

Carlsmed.png

AdvaMed Praises Administration’s “Women’s Health Research” Initiative ...

AdvaMed

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page